Skip to main content
OpenTrials
Completed

NCT Number: NCT04488874

Sodium Lactate and Brain Relaxation (LSD)

Resection surgery of brain tumors by craniotomy requires efficient brain relaxation intraoperatively in order to avoid injuries caused by the brain retractors (such as ischemic-reperfusion and cerebral oedema). The gold standard for the brain relaxation during a surgery is Mannitol 20%.

Molar sodium lactate is now used to induce brain relaxation in patients with traumatic brain injury and intracranial hypertension due to its osmotic effect. Furthermore, the injection of sodium lactate may lead to better neuronal metabolism during cerebral aggression, and may participate to the reduction of cerebral oedema and secondary injuries.

LSD is a pilot randomised trial which tries to assess the interest of intravenous administration of molar Sodium Lactate on the quality of brain relaxation in surgical resection of supratentorial brain tumors by craniotomy.

The primary outcome measure is the quality of brain relaxation, evaluated by neurosurgeon at the opening of the dura, by a validated brain relaxation scale.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sodium Lactate Brain Diseases Brain Relaxation Central Nervous System Diseases Intracranial Hypertension Nervous System Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU de Besançon

Besançon, France

About this study

It's a prospective, comparative, randomised, double blinded study. It will enroll 50 patients undergoing resection surgery of supratentorial brain tumor. They will be randomly divided in 2 groups of 25 patients each : Mannitol 20% and molar Sodium Lactate. The only difference between the 2 groups is the drug used for brain relaxation at the surgical incision : Mannitol or Sodium lactate.

The outcome measures include quality of brain relaxation, need of "rescue" therapy to get an adequate brain relaxation, electrolytes alterations, change in lactate serum level, quantification of post operative brain swelling by MRI, time of extubation, Glasgow Coma Scale, neuropsychological evaluation, blood levels of Protein S100-β, NSE (Neuron-Specific Enolase) and GFAP Glial Fibrillary Acid Protein), morbidity and mortality during 30 days after surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with ASA 1, ASA 2 ou ASA 3, meaning they don't have any unstable comorbidities which could be a threat to life.
  • Scheduled surgery for resection of supratentorial brain tumors by craniotomy under general anesthesia
  • Unilateral brain tumor
  • Deviation of the falx cerebri > 3mm on the preoperative imaging
  • Pharmacological brain relaxation required by the neurosurgeon in charge of the patient.
  • Patient who has been informed and who signed the free informed consent to participate to the study. Meaning the patient understood the purpose and the procedures required by the study and agreed to participate and obey the requirements and restrictions of this study.
  • Affiliation to a social security system or recipient of a such system.

Exclusion criteria

  • Emergency surgery
  • Age < 18 years old or > 75 years old
  • ASA score IV-V
  • Legal incapability or limited legal capacity
  • Patient who will unlikely cooperate to the study and/or poor cooperation foreseen by the investigator
  • Preoperative Glasgow score < 13
  • Pregnant woman and/or breastfeeding
  • Body index masse< 18 kg.m-2 ou > 30 kg.m-2
  • Preoperative hyponatremia < 130mmol/l or hypernatremia > 145 mmol/l
  • Osmotherapy in the 24 hours prior to the surgery (Mannitol, Hypertonic saline, Sodium lactate)
  • Congestive heart failure
  • Moderate ou severe chronic kidney disease, defined by a creatinine clearance (MDRD) < 60 ml/min
  • End-stage liver disease (Child Pugh ≥ B7)
  • Myasthenia gravis
  • External ventricular drain or ventriculoperitoneal shunt of cerebrospinal fluid
  • Allergy to Mannitol 20% or one of his excipients
  • Allergy to Sodium Lactate or one of his excipients
  • Contraindication for propofol
  • Allergy to anesthetic agents (propofol, remifentanil, cisatracurium)
  • Refusal of consent
  • Patient within the exclusion period of another study or planned by the "national file of volunteers"
  • Medical history of cognitive disorders or demencia

Treatment and study plan

Sodium lactate

Drug

Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.

Sodium Lactate and Mannitol 20% are used at an equimolar dose

Mannitol 20% Infusion

Drug

Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.

Primary outcomes

  1. Quality of brain relaxation

    Time frame: intraoperative

    An adequate brain relaxation is evaluated by the neurosurgeon with a stage 1 (perfectly relaxed) or 2 (acceptably relaxed) of the brain swelling score validated by Todd et al. The brain swelling score is a four-point-scale: 1 (normal brain; no swelling); 2 (minimal swelling, but acceptable); 3 (serious swelling but no specific change in management required); or 4 (severe brain swelling requiring some intervention). Todd et al. reported a significant Relationship between intracranial pressure and the brain swelling score. The brain swelling score is the consensual tool used in clinical trials to assess the clinical effectiveness of brain relaxative therapy.

Secondary outcomes

  1. Necessity for "rescue" therapy

    Time frame: intraoperative

    Proportion of patients who needed a "rescue" therapy in order to improve the brain relaxation and to enable the surgery. "Rescue" therapy consists of the administration of an additional dose of Mannitol 20% 0.25g/kg, deepening the anesthesia (BIS between 20 and 40) or the administration of an intravenous dose of Thiopental 5mg/kg.

  2. Electrolytes alterations

    Time frame: 30 minutes, 60 minutes, 180 minutes, 24 hours and 48 hours after completion of sodium lactate or mannitol infusion

    Variations of natremia (mmol/L), kaliemia (mmol/L), pH and serum osmolarity (mosmol/L) after administration of the osmotherapy.

  3. Changes of lactatemia

    Time frame: 30 minutes, 60 minutes, 180 minutes, 24 hours and 48 hours after completion of sodium lactate or mannitol infusion

    Variations of lactatemia (mmol/L) after administration of the osmotherapy

  4. Volume of post operative brain edema

    Time frame: Day 2 after surgery

    Measurement of the volume of the post operative brain edema by MRI

  5. Glasgow Coma Scale

    Time frame: preoperative, at day 1 and day 2 postoperative

    Assessment of Glasgow coma scale (scale assessing level of conscioussness ranging from 3 = deep unconsciousness to 15 = normal consciousness)

  6. Extubation

    Time frame: Within 2 hours after the end of surgery

    Time between the end of anesthesia and extubation (min)

  7. Neurological recovery

    Time frame: preoperative and Day 2 after surgery

    Neurological revcovery will be assessed comparing the results of a battery of validated neurocognitive tests performed the day before surgery and at Day 2 after surgery.

  8. Protein S100-β

    Time frame: Prior to sodium lactate or mannitol infusion and at 24 hours and at 48 hours after completion of sodium lactate or mannitol infusion

    change in blood level of Protein S100-β

  9. Neuron-Specific Enolase (NSE)

    Time frame: Prior to sodium lactate or mannitol infusion and at 24 hours and at 48 hours after completion of sodium lactate or mannitol infusion

    Change in blood level of Neuron-Specific Enolase (NSE)

  10. Glial Fibrillary Acid Protein (GFAP)

    Time frame: Prior to sodium lactate or mannitol infusion and at 24 hours and at 48 hours after completion of sodium lactate or mannitol infusion

    Change in blood level of Neuron-Specific Enolase (NSE)

  11. Morbidity

    Time frame: Within 30 days after surgery

    Incidence of heart rhythm disorders during the first 48 hours postoperative, intensive care unit length of stay, hospital length of stay, duration of mechanical ventilation, postoperative complications

  12. Mortality

    Time frame: Within 30 days after surgery

    Mortality within 30 days after surgery

  13. Karnofsky performance scale

    Time frame: preoperative and at day 30 after surgery

    The Karnofsky performance scale index is an assessment tool for functional impairment. The lower the Karnofsky score, the worst functional impairment, and in most serious illnesses, the worse likelihood of survival. The Karnofsky performance scale ranges from 0 (dead patient) to 100 (normal no complaints, no evidence of disease).

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Official study title

Clinical Effectiveness of Hypertonic Sodium Lactate Infusion for Intraoperative Brain Relaxation in Patients Undergoing Scheduled Craniotomy for Supratentorial Brain Tumor Resection: Study Protocol of a Single Center Double-blind Randomized Controlled Phase II Pilot Trial

Acronym: LSD

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jul 28, 2020
Registry last updated
Sep 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.